As Geneoscopy kicked off a clinical trial for its at-home screening test for colorectal cancer, it employed a novel approach that bucks the traditional model for securing participants in the study. Its strategy is one it says offers a solution to a major, long-standing problem: an underrepresentation of minorities in the clinical trials. The St. Louis startup says it’s already seeing promising results.